MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Commentary
Paving the way for a more integrated and efficient mobility future in Hong Kong